Standout Papers

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis ... 2015 2026 2018 2022 640
  1. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Iain B. McInnes, Philip J. Mease et al. The Lancet

Immediate Impact

6 from Science/Nature 58 standout
Sub-graph 1 of 20

Citing Papers

From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
2 intermediate papers

Works of Gregory Ligozio being referenced

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Gregory Ligozio 571 682 251 380 25 1.3k
Ulla Lindqvist 624 439 136 39 51 1.4k
Nathan Bennett 94 341 167 177 20 1.1k
Anikó Kapitány 382 226 151 215 40 1.1k
Joseph P. Michalski 299 289 251 155 36 1.1k
P Maddison 955 379 164 24 37 1.6k
Danila Guagnozzi 451 175 743 214 45 1.3k
Maria Luisa Pacor 462 215 94 61 47 1.3k
A K Bhalla 257 266 241 260 29 1.6k
Frédéric Féger 316 863 192 31 30 1.6k
Winston Sequeira 461 229 256 36 37 1.0k

All Works

Loading papers...

Rankless by CCL
2026